| 4.08 0.33 (8.8%) | 07-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.76 | 1-year : | 6.69 |
| Resists | First : | 4.93 | Second : | 5.73 |
| Pivot price | 4.64  |
|||
| Supports | First : | 3.65 | Second : | 3.03 |
| MAs | MA(5) : | 3.99 |
MA(20) : | 4.79 |
| MA(100) : | 4.58 |
MA(250) : | 4.14 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.7 |
D(3) : | 14.4 |
| RSI | RSI(14): 42 |
|||
| 52-week | High : | 5.73 | Low : | 3.05 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PYPD ] has closed above bottom band by 28.6%. Bollinger Bands are 260.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 6 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 4.34 - 4.36 | 4.36 - 4.38 |
| Low: | 3.91 - 3.94 | 3.94 - 3.96 |
| Close: | 4.05 - 4.08 | 4.08 - 4.11 |
PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.
Thu, 30 Jul 2026
PolyPid Schedules 8:30 a.m. Webcast for Aug. 12 Results - Stock Titan
Thu, 30 Jul 2026
PYPD|PolyPid Ltd|Price:4.040|Chg%:+0.290 - TradingKey
Thu, 30 Jul 2026
PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Wed, 29 Jul 2026
PolyPid rises as lead product granted FDA priority review - Seeking Alpha
Wed, 29 Jul 2026
FDA Priority Review Boosts PolyPid (PYPD) Outlook Amid Valuation Challenges - GuruFocus
Wed, 29 Jul 2026
PolyPid (Nasdaq: PYPD) gets FDA Priority Review and $15M milestone - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 19 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 21.2 (%) |
| Held by Institutions | 34.8 (%) |
| Shares Short | 283 (K) |
| Shares Short P.Month | 146 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -115.1 % |
| Return on Equity (ttm) | -758.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.66 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -2.35 |
| PEG Ratio | 0 |
| Price to Book value | 8.86 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|